This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.

Note: We can assist only if the medicine is unavailable in your country.”

MitoGENE supports patients and doctors in India by assisting with:

  • Documentation and regulatory filings
  • Import coordination for Mektovi (binimetinib)
  • Secure delivery compliant with Indian healthcare regulations

This ensures a safe and legal pathway for Indian patients seeking international cancer medicines like Mektovi (binimetinib) when no local treatment alternatives are available.

Need Help Accessing Mektovi (binimetinib) in India?
If you or your loved one has been prescribed Mektovi by an oncologist, MitoGENE can support you with:

  • Fast-track documentation
  • International sourcing and delivery
  • Expert NPP compliance

Reach out to us via the inquiry form below.

MEKTOVI (binimetinib)

Mektovi (binimetinib) is a targeted cancer therapy used in combination with Braftovi (encorafenib) to treat adults with unresectable or metastatic melanoma that has a BRAF V600E or V600K mutation, as detected by an FDA-approved test. Mektovi is a MEK inhibitor that works by interfering with the MAPK/ERK signaling pathway, which plays a key role in the growth of certain cancers.

Access in India (Named Patient Program)

Mektovi (binimetinib) is not commercially available in India. However, patients may be able to access this medicine through the Named Patient Program (NPP), a legal framework that allows Indian patients to import medications not yet approved domestically, under the supervision of a licensed treating physician.

Medicine Approved by

  • United States (U.S.) – U.S. FDA
  • European Union (EU) – EMA
  • Australia – TGA
  • Canada – Health Canada

Disease Indications: Skin Cancer

Disease Indications: Skin Cancer

Manufacturer: Pierre Fabre Medicament

Usage: Oral

Available Dosage Form & Package:

  • 84 tablets of 15 mg
  • 168 tablets of 15 mg

Shipping:

Room Temperature Shipping.  Mektovi (binimetinib) is shipped under controlled room temperature conditions (15°C to 25°C) using standard logistics procedures.trolled room temperature range of 15°C to 25°C throughout transit.

What is Mektovi (binimetinib)?

Mektovi is a prescription medication used in combination with Braftovi (encorafenib) to treat adult patients with unresectable or metastatic melanoma that tests positive for the BRAF V600E or V600K mutation. It is part of a class of drugs called MEK inhibitors, which work by blocking abnormal signals that cause cancer cells to grow.

This medicine is only effective if your tumor carries the specific BRAF mutation. A diagnostic test will be performed before starting the treatment.

How Does Mektovi Work?

Mektovi blocks MEK1 and MEK2 proteins in the MAPK pathway, which is overactive in cancers with BRAF mutations. By inhibiting this pathway in combination with BRAFT inhibitor Braftovi, Mektovi helps slow tumor growth and increase survival in eligible patients.

Important Safety Information & Common Side Effects

Serious Risks Include:

  • Cardiomyopathy: Reduced heart function. Monitoring via echocardiogram is required.
  • Retinal vein occlusion or detachment: Can cause vision problems or loss.
  • Interstitial lung disease: Inflammation of lung tissue.
  • Bleeding problems
  • Elevated liver enzymes

Common Side Effects May Include:

  • Nausea, vomiting
  • Diarrhea
  • Abdominal pain
  • Fatigue
  • Muscle spasms
  • Rash
  • Dry skin
  • Increased liver enzymes (AST/ALT)
  • Decreased appetite
  • Anemia
  • Peripheral edema

Patients should be monitored regularly for cardiac, liver, and ocular side effects. This is not a complete list. Speak to your physician for personalized risk-benefit analysis.

References

  1. Prescribing Information: Mektovi (binimetinib) – Pfizer
    https://labeling.pfizer.com/ShowLabeling.aspx?id=11387
  2. FDA Approval Letter – Mektovi (binimetinib)
    https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/210498Orig1s000ltr.pdf
  3. EMA Public Assessment Report – Mektovi
    https://www.ema.europa.eu/en/documents/assessment-report/mektovi-epar-public-assessment-report_en.pdf
  4. Product Monograph – Health Canada
    https://pdf.hres.ca/dpd_pm/00046493.PDF
  5. ClinicalTrials.gov – Binimetinib and Encorafenib in BRAF-Mutant Melanoma (NCT02928224)
    https://clinicaltrials.gov/ct2/show/NCT02928224

Disclaimer: Mektovi (binimetinib) is not approved for commercial sale in India. Access is provided strictly for personal use under physician supervision in accordance with Indian regulatory guidelines through the Named Patient Program (NPP). MitoGENE does not market, advertise, or sell unapproved drugs. All content is for informational purposes and not a substitute for professional medical advice.

How to Access Mektovi (binimetinib) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?

If Mektovi (binimetinib) is not yet approved or commercially available in India, MitoGENE can assist you in accessing it legally through the Named Patient Program (NPP). Here’s how the process works:

    Upload Prescription

    Upload Patient Consent Form

    Patient Consent Form
    Download

    Please download and complete this form, including your signature, and attach it to the request form or email it to info@mitogene.org along with the patient details.